CSS LLC’s Acadia Pharmaceuticals ACAD Stock Holding History

CSS LLC’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-40,000	Closed	-$1.03M	–	1061
2021 Q1	$1.03M	Buy	+40,000	New	+$1.76M	0.04%	377

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CSS LLC's ACAD Position: Q1 2022 in Review

CSS LLC sold out of Acadia Pharmaceuticals (ACAD) in Q1 2022, closing a stake of 5,200 shares — an estimated $121K sold.

CSS LLC first reported a position in ACAD in Q1 2021 and held it in 4 quarters. The position peaked at $496K in Q1 2021. 263 funds tracked by Wall St. Rank hold ACAD as of Q1 2022.

CSS LLC reported no remaining Acadia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
CSS LLC sold 5,200 Acadia Pharmaceuticals shares in Q1 2022, an estimated $121K.
CSS LLC first reported a position in Acadia Pharmaceuticals in Q1 2021 and held it in 4 quarters.
CSS LLC's Acadia Pharmaceuticals position peaked at $496K in Q1 2021.
263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2022.

Based on CSS LLC's 13F filing for Q1 2022, filed 16 May 2022.